How to buy Biocept (BIOC) shares in Australia

Learn how to easily invest in Biocept shares.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Biocept Inc is a diagnostics & research business with stocks listed in the US. Biocept shares (BIOC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$3.87 – an increase of 4.03% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Biocept

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Biocept. Find the share by name or ticker symbol: BIOC. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Biocept reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$3.87, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Biocept, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Biocept. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Biocept stock price (NASDAQ:BIOC)

Use our graph to track the performance of BIOC stocks over time.

Biocept shares at a glance

Information last updated 2021-11-27.
52-week rangeUS$3.26 - US$8.38
50-day moving average US$3.8774
200-day moving average US$4.4357
Target priceUS$13
PE ratio 17.7626
Dividend yield N/A (0%)
Earnings per share (TTM) US$0.219

Where to buy Biocept stock

Name Product Standard brokerage for US shares Currency conversion fee Markets
eToro (global stocks)
US$0
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
US$0
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
US$0
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares
Earn up to 15,000 Qantas frequent flyer points when you transfer an exisiting balance or trade. Offer valid for all new and existing Superhero members until 28 February.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
Saxo Capital Markets (Classic account)
US$4
1%
ASX shares, Global shares, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CommSec Share Trading Account
US$19.95
0.60%
ASX shares, Global shares, Options trading, ETFs
Trade with Australia's largest online stockbroking firm.
Enjoy fast, simple and affordable trades, with market leading research and broker recommendations all in one platform
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Biocept stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Biocept share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Considering buying Biocept shares?

Before you consider Biocept, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.

Show me how

Biocept price performance over time

Historical closes compared with the last close of $3.87

1 week (2021-11-26) -0.51%
1 month (2021-11-03) -2.03%
3 months (2021-09-03) 5.74%
6 months (2021-06-03) -9.58%
1 year (2020-12-03) -24.41%
2 years (2019-12-03) -28.28%
3 years (2018-12-03) -63.83%
5 years (2016-12-02) -52.22%

Stocks similar to Biocept

Is Biocept under- or over-valued?

Valuing Biocept stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biocept's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Biocept's P/E ratio

Biocept's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Biocept shares trade at around 18x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Biocept's EBITDA

Biocept's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$4.7 million (£0.0 million).

The EBITDA is a measure of a Biocept's overall financial performance and is widely used to measure a its profitability.

Biocept financials

Revenue TTM US$65.8 million
Operating margin TTM 5.15%
Gross profit TTM US$6.1 million
Return on assets TTM 4.47%
Return on equity TTM 10.1%
Profit margin 4.71%
Book value 2.403
Market capitalisation US$65.5 million

TTM: trailing 12 months

Biocept share dividends

We're not expecting Biocept to pay a dividend over the next 12 months.

Have Biocept's shares ever split?

Biocept's shares were split on a 1:10 basis on 7 September 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biocept shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Biocept shares which in turn could have impacted Biocept's share price.

Biocept share price volatility

Over the last 12 months, Biocept's shares have ranged in value from as little as US$3.26 up to US$8.38. A popular way to gauge a stock's volatility is its "beta".

BIOC.US volatility(beta: 0.52)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biocept's is 0.5174. This would suggest that Biocept's shares are less volatile than average (for this exchange).

Biocept overview

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. It has a partnership with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site